PFIZER's Rx DIFLUCAN ONE-TABLET TREATMENT FOR VAGINAL CANDIDIASIS
This article was originally published in The Tan Sheet
Executive Summary
PFIZER's Rx DIFLUCAN ONE-TABLET TREATMENT FOR VAGINAL CANDIDIASIS represents a new competitive threat to OTC vaginal yeast infection brands, which have been beleaguered in the past year by private-label knock-offs, Pfizer's one-tablet, 150 mg Diflucan (fluconazole) dosage regimen for vaginal candidiasis was approved by FDA on June 30 with a "6P" rating by the agency, denoting a new indication of an already marketed product given a priority review. Pfizer announced the approval on July 7.